SCHEMBL4528462

SCHEMBL4528462

O=Cc1ccc(Br)cc1N1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
MAPT P10636 5/20 0.45
ALDH1A3 P47895 5/20 0.45
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
ERN1 O75460 1/20 0.43
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NCF1 P14598 1/20 0.38
CYP2A6 P11509 2/20 0.38
IP6K1 Q92551 1/20 0.37
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471820 0.98 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTALDH1A3NPC1
SCHEMBL6104298 0.86 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2MAPTALDH1A3NPC1
SCHEMBL1277259 0.85 PRKDC (0.51) ALDH1A1SMN1; SMN2MAPTALDH1A3HTT
SCHEMBL3690553 0.85 HTT (0.48) ALDH1A1SMN1; SMN2MAPTHTTERN1
SCHEMBL6103152 0.84 ALDH1A3 (0.49) ALDH1A1SMN1; SMN2MAPTALDH1A3NPC1
SCHEMBL6103643 0.84 ALDH1A3 (0.49) ALDH1A1SMN1; SMN2MAPTALDH1A3NPC1
SCHEMBL6104382 0.84 ALDH1A3 (0.49) ALDH1A1SMN1; SMN2MAPTALDH1A3NPC1
SCHEMBL25692327 0.83 ERN1 (0.39) ALDH1A1SMN1; SMN2MAPTERN1MEN1
SCHEMBL30642982 0.83 ERN1 (0.39) ALDH1A1SMN1; SMN2MAPTERN1MEN1
SCHEMBL26618064 0.82 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPTNPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018004-B2 Carbamate compounds and methods of making and using same H. LUNDBECK A/S (DK) 2024-06-25 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2023-10-05 US disclosed
US-11530189-B2 Carbamate compounds and methods of making and using same H. LUNDBECKA/S (DK) 2022-12-20 US disclosed
US-11530189-B2 Carbamate compounds and methods of making and using same H. LUNDBECKA/S (DK) 2022-12-20 US disclosed
CN-107982266-B Carbamate compounds and methods of making and using the same H.隆德贝克有限公司 2021-07-30 CN disclosed
US-20210188793-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME LUNDBECK LA JOLLA RESEARCH CENTER, INC. 2021-06-24 US disclosed
US-20210188793-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME LUNDBECK LA JOLLA RESEARCH CENTER, INC. 2021-06-24 US disclosed
US-11021453-B2 Carbamate compounds and methods of making and using same LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-06-01 US disclosed
US-20150148330-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2015-05-28 US disclosed
US-20150148330-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2015-05-28 US disclosed
US-20150148330-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2015-05-28 US disclosed
EP-2800565-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2014-11-12 EP disclosed
WO-2013103973-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-07-11 WO disclosed
WO-2013103973-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-07-11 WO disclosed
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors BERTHEL STEVEN JOSEPH 2009-04-23 US disclosed
EP-1812409-A1 AMINOQUINAZOLINES COMPOUNDS F. Hoffmann-Roche AG (CH) 2007-08-01 EP disclosed
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2006-09-21 US disclosed
WO-2006050843-A1 AMINOQUINAZOLINES COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530189-B2 Carbamate compounds and methods of making and using same ABHD6, ABHD16A, RABL6 ALDH1A1 2487/4885SMN1; SMN2 2374/4885MAPT 2367/4885
US-11021453-B2 Carbamate compounds and methods of making and using same ABHD6, ABHD16A, RABL6 ALDH1A1 2385/4885SMN1; SMN2 2659/4885MAPT 2284/4885
US-20210188793-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, RABL6 ALDH1A1 2487/4885SMN1; SMN2 2374/4885MAPT 2367/4885
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors PTPN5, PTPN1, PTPN7 ALDH1A1 1591/4885SMN1; SMN2 4747/4885MAPT 3752/4885
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors PTPN5, PTPN1, PTPN7 ALDH1A1 1591/4885SMN1; SMN2 4747/4885MAPT 3752/4885
US-20230312499-A1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME ABHD6, ABHD16A, RABL6 ALDH1A1 2487/4885SMN1; SMN2 2374/4885MAPT 2367/4885
US-20150148330-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABHD6, ABHD16A, PRMT6 ALDH1A1 2002/4885SMN1; SMN2 1644/4885MAPT 4222/4885
US-12018004-B2 Carbamate compounds and methods of making and using same ABHD6, ABHD16A, RABL6 ALDH1A1 2487/4885SMN1; SMN2 2374/4885MAPT 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.